The complexities and misaligned incentives within our healthcare system have affected the pace of biosimilar adoption in the US.

Precision’s Kellie Rademacher discusses how educating providers and members on the available evidence for different products in biosimilar categories, as well as the potential savings, can improve demand and uptake.

Read the full article here!